Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition
- 1 June 2007
- journal article
- Published by Springer Science and Business Media LLC in Nature Reviews Cancer
- Vol. 7 (6), 475-485
- https://doi.org/10.1038/nrc2152
Abstract
Contrary to initial expectations, angiogenesis inhibitors can cause toxicities in patients with cancer. The toxicity profiles of these inhibitors reflect the disturbance of growth factor signalling pathways that are important for maintaining homeostasis. Experiences with angiogenesis inhibitors in clinical trials indicate that short-term toxicities are mostly manageable. However, these agents will also be given in prolonged treatment strategies, so we need to anticipate possible long-term toxicities. In addition, understanding the molecular mechanisms involved in the toxicity of angiogenesis inhibition should allow more specific and more potent inhibitors to be developed.Keywords
This publication has 127 references indexed in Scilit:
- Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenibEuropean Journal Of Cancer, 2007
- The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myelomaProceedings of the National Academy of Sciences of the United States of America, 2006
- The role of platelet adhesion receptor GPIbα far exceeds that of its main ligand, von Willebrand factor, in arterial thrombosisProceedings of the National Academy of Sciences of the United States of America, 2006
- Predicting benefit from anti-angiogenic agents in malignancyNature Reviews Cancer, 2006
- Artery/Vein Specification Is Governed by Opposing Phosphatidylinositol-3 Kinase and MAP Kinase/ERK SignalingCurrent Biology, 2006
- Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?European Journal Of Cancer, 2006
- Cutaneous side-effects of kinase inhibitors and blocking antibodiesThe Lancet Oncology, 2005
- Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trialsAnnals Of Oncology, 2005
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Angiogenic growth factors and hypertensionAngiogenesis, 2004